StatusFlow is a stable preparation of human peripheral leukocytes and erythrocytes designed for use as a control in immunopheno-typing when evaluating RBC lysis, antibody reactivity, instrument set-up, and instrument performance by flow cytometry. Assay values are reported as a percent of total lymphocytes and as the number of cells for the following phenotypes: CD3+, CD3+/CD4+, CD3+/CD8+, CD19+, CD3-/CD16+56+, CD20+, CD2+, and HLA-DR+. Target values (for research use only) are also provided for the following CD markers: kappa, lambda, CD8+/CD38+, CD33+/CD14+, CD7+/CD3+, CD5+, CD22+/CD3-, and CD13+. Target values for CD45 and CD14, which are intended for gating purposes only, are also included. StatusFlow has a closed vial stability of 45 days with an open vial stability of 9 thermal cycles.


  • 45-day closed vial stability; 1 QC month
  • 9 thermal cycles open vial stability
  • Packaged in 2.5mL pierceable Hemogard tubes
  • Assayed for BD Biosciences FACS series, BECKMAN COULTER FC500, Elite, Epics, Profile and Epics XL, and Manual Methods

 Catalog NumberDescription
Hemogard TubesFC2022 x 2.5mL
Hemogard TubesFC3023 x 2.5mL
Hemogard TubesFC4044 x 4mL
Hemogard TubesFC5025 x 2.5mL
Hemogard TubesFC5045 x 4mL

Assay Sheet